Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity
Serological assays have been widely employed during the coronavirus disease 2019 (COVID-19) pandemic to measure antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to track seroconversion in populations. However, currently available assays do not allow determinatio...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/13/7/1371 |
| _version_ | 1827686721248034816 |
|---|---|
| author | Thomas Phelan Jean Dunne Niall Conlon Clíona Ní Cheallaigh W. Mark Abbott Raquel Faba-Rodriguez Fatima Amanat Florian Krammer Mark A. Little Gerry Hughes Colm Bergin Colm Kerr Sudharshana Sundaresan Aideen Long William McCormack Gareth Brady |
| author_facet | Thomas Phelan Jean Dunne Niall Conlon Clíona Ní Cheallaigh W. Mark Abbott Raquel Faba-Rodriguez Fatima Amanat Florian Krammer Mark A. Little Gerry Hughes Colm Bergin Colm Kerr Sudharshana Sundaresan Aideen Long William McCormack Gareth Brady |
| author_sort | Thomas Phelan |
| collection | DOAJ |
| description | Serological assays have been widely employed during the coronavirus disease 2019 (COVID-19) pandemic to measure antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to track seroconversion in populations. However, currently available assays do not allow determination of neutralization capacity within the assay protocol. Furthermore, commercial serology assays have a high buy-in cost that is inaccessible for many research groups. We have replicated the serological enzyme-linked immunosorbent assay for the detection of SARS-CoV-2 antibody isotypes, developed at the Icahn School of Medicine at Mount Sinai, New York. Additionally, we have modified the protocol to include a neutralization assay with only a minor modification to this protocol. We used this assay to screen local COVID-19 patient sera (<i>n</i> = 91) and pre-COVID-19 control sera (<i>n</i> = 103), and obtained approximate parity with approved commercial anti-nucleoprotein-based assays with these sera. Furthermore, data from our neutralization assay closely aligns with that generated using a spike-based pseudovirus infection model when a subset of patient sera was analyzed. |
| first_indexed | 2024-03-10T09:19:48Z |
| format | Article |
| id | doaj.art-6b2563b71cab4e91980ae4ca887818c7 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T09:19:48Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-6b2563b71cab4e91980ae4ca887818c72023-11-22T05:15:01ZengMDPI AGViruses1999-49152021-07-01137137110.3390/v13071371Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization CapacityThomas Phelan0Jean Dunne1Niall Conlon2Clíona Ní Cheallaigh3W. Mark Abbott4Raquel Faba-Rodriguez5Fatima Amanat6Florian Krammer7Mark A. Little8Gerry Hughes9Colm Bergin10Colm Kerr11Sudharshana Sundaresan12Aideen Long13William McCormack14Gareth Brady15Department of Clinical Medicine, Trinity Translational Medicine Institute, School of Medicine, Trinity College Dublin, D08 W9RT Dublin, IrelandDepartment of Immunology, St. James’s Hospital, D08 NHY1 Dublin, IrelandDepartment of Immunology, St. James’s Hospital, D08 NHY1 Dublin, IrelandDepartment of Clinical Medicine, Trinity Translational Medicine Institute, School of Medicine, Trinity College Dublin, D08 W9RT Dublin, IrelandPeak Proteins Ltd., Alderley Park, Mereside, Macclesfield SK10 4TG, UKPeak Proteins Ltd., Alderley Park, Mereside, Macclesfield SK10 4TG, UKDepartment of Microbiology, Icahn School of Medicine, Mount Sinai, New York, NY 10029-5674, USADepartment of Microbiology, Icahn School of Medicine, Mount Sinai, New York, NY 10029-5674, USATrinity Health Kidney Centre, Trinity Translational Medicine Institute, Trinity College Dublin, St. James’ Hospital Campus, D08 W9RT Dublin, IrelandDepartment of Clinical Medicine, Trinity Translational Medicine Institute, School of Medicine, Trinity College Dublin, D08 W9RT Dublin, IrelandDepartment of Clinical Medicine, Trinity Translational Medicine Institute, School of Medicine, Trinity College Dublin, D08 W9RT Dublin, IrelandDepartment of Clinical Medicine, Trinity Translational Medicine Institute, School of Medicine, Trinity College Dublin, D08 W9RT Dublin, IrelandDepartment of Clinical Medicine, Trinity Translational Medicine Institute, School of Medicine, Trinity College Dublin, D08 W9RT Dublin, IrelandDepartment of Clinical Medicine, Trinity Translational Medicine Institute, School of Medicine, Trinity College Dublin, D08 W9RT Dublin, IrelandDepartment of Clinical Medicine, Trinity Translational Medicine Institute, School of Medicine, Trinity College Dublin, D08 W9RT Dublin, IrelandDepartment of Clinical Medicine, Trinity Translational Medicine Institute, School of Medicine, Trinity College Dublin, D08 W9RT Dublin, IrelandSerological assays have been widely employed during the coronavirus disease 2019 (COVID-19) pandemic to measure antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to track seroconversion in populations. However, currently available assays do not allow determination of neutralization capacity within the assay protocol. Furthermore, commercial serology assays have a high buy-in cost that is inaccessible for many research groups. We have replicated the serological enzyme-linked immunosorbent assay for the detection of SARS-CoV-2 antibody isotypes, developed at the Icahn School of Medicine at Mount Sinai, New York. Additionally, we have modified the protocol to include a neutralization assay with only a minor modification to this protocol. We used this assay to screen local COVID-19 patient sera (<i>n</i> = 91) and pre-COVID-19 control sera (<i>n</i> = 103), and obtained approximate parity with approved commercial anti-nucleoprotein-based assays with these sera. Furthermore, data from our neutralization assay closely aligns with that generated using a spike-based pseudovirus infection model when a subset of patient sera was analyzed.https://www.mdpi.com/1999-4915/13/7/1371antibodyenzyme-linked immunosorbent assayneutralizationSARS-CoV-2serologypseudovirus infection model |
| spellingShingle | Thomas Phelan Jean Dunne Niall Conlon Clíona Ní Cheallaigh W. Mark Abbott Raquel Faba-Rodriguez Fatima Amanat Florian Krammer Mark A. Little Gerry Hughes Colm Bergin Colm Kerr Sudharshana Sundaresan Aideen Long William McCormack Gareth Brady Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity Viruses antibody enzyme-linked immunosorbent assay neutralization SARS-CoV-2 serology pseudovirus infection model |
| title | Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity |
| title_full | Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity |
| title_fullStr | Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity |
| title_full_unstemmed | Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity |
| title_short | Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity |
| title_sort | dynamic assay for profiling anti sars cov 2 antibodies and their ace2 spike rbd neutralization capacity |
| topic | antibody enzyme-linked immunosorbent assay neutralization SARS-CoV-2 serology pseudovirus infection model |
| url | https://www.mdpi.com/1999-4915/13/7/1371 |
| work_keys_str_mv | AT thomasphelan dynamicassayforprofilingantisarscov2antibodiesandtheirace2spikerbdneutralizationcapacity AT jeandunne dynamicassayforprofilingantisarscov2antibodiesandtheirace2spikerbdneutralizationcapacity AT niallconlon dynamicassayforprofilingantisarscov2antibodiesandtheirace2spikerbdneutralizationcapacity AT clionanicheallaigh dynamicassayforprofilingantisarscov2antibodiesandtheirace2spikerbdneutralizationcapacity AT wmarkabbott dynamicassayforprofilingantisarscov2antibodiesandtheirace2spikerbdneutralizationcapacity AT raquelfabarodriguez dynamicassayforprofilingantisarscov2antibodiesandtheirace2spikerbdneutralizationcapacity AT fatimaamanat dynamicassayforprofilingantisarscov2antibodiesandtheirace2spikerbdneutralizationcapacity AT floriankrammer dynamicassayforprofilingantisarscov2antibodiesandtheirace2spikerbdneutralizationcapacity AT markalittle dynamicassayforprofilingantisarscov2antibodiesandtheirace2spikerbdneutralizationcapacity AT gerryhughes dynamicassayforprofilingantisarscov2antibodiesandtheirace2spikerbdneutralizationcapacity AT colmbergin dynamicassayforprofilingantisarscov2antibodiesandtheirace2spikerbdneutralizationcapacity AT colmkerr dynamicassayforprofilingantisarscov2antibodiesandtheirace2spikerbdneutralizationcapacity AT sudharshanasundaresan dynamicassayforprofilingantisarscov2antibodiesandtheirace2spikerbdneutralizationcapacity AT aideenlong dynamicassayforprofilingantisarscov2antibodiesandtheirace2spikerbdneutralizationcapacity AT williammccormack dynamicassayforprofilingantisarscov2antibodiesandtheirace2spikerbdneutralizationcapacity AT garethbrady dynamicassayforprofilingantisarscov2antibodiesandtheirace2spikerbdneutralizationcapacity |